Zealand Pharma Announces Positive Results from Phase 3 Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism (CHI)
Company announcement – No. 22 / 2022 Zealand Pharma Announces Positive Results from Phase 3 Trial of Dasiglucagon in Pediatric...